secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibikase Therapeutics, Inc. (IKT)
CIK:        0001750149
Form:       8-K
Filed at:   2024-01-16T23:59:59+00:00
Accession:  0001193125-24-008593
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inhibikase CFO Joseph Frattaroli to retire; Garth Lees-Rolfe promoted as successor
--------------------------------------------------------------------------------

- Joseph Frattaroli to retire as CFO effective March 31, 2024; vested stock option exercise period extended.
- Garth Lees-Rolfe, current VP of Finance since Nov 2022, will become CFO upon Frattaroli's retirement.
- Lees-Rolfe previously VP Finance at F-Star and spent 16 years in public practice, including at Ernst & Young.
- Retirement is not due to any disagreement with the Company; transition is planned and orderly.
- Compensation for Lees-Rolfe as CFO not yet determined; to be disclosed in a future 8-K amendment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750149/000119312524008593/0001193125-24-008593-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750149/000119312524008593/d125920d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-008593

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer